Artelo Biosciences, Inc. (ARTL) Stock Price & Analysis
Artelo Biosciences, Inc. (ARTL) fell 2.89% to USD 6.04 as of September 8, 2026 at 06:24 UTC, according to Nexqual real-time market data.
ARTL last closed at USD 6.04; the session ranged USD 5.97–6.35 on volume of 27,361 shares. Market capitalization is —, with a 52-week range of USD 4.68–179.19 (NCM). Source: Nexqual, September 8, 2026 at 06:24 UTC.
Key Statistics (as of September 8, 2026 at 06:24 UTC)
| Price | USD 6.04 |
|---|---|
| Change | ▼ 2.89% (down) |
| Previous Close | USD 6.04 |
| Open | USD 6.04 |
| Day Range | USD 5.97 – 6.35 |
| 52-Week Range | USD 4.68 – 179.19 |
| Volume | 27,361 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (ARTL)
Nexqual's technical model rates ARTL "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 06:24 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 33.09 (neutral) |
| vs SMA50 | Below (USD 7.9) |
| MACD | -0.54 (negative) |
From Artelo Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- These data are aligned with safety outcomes observed in Phase 1 of CAReS, supporting ART27.13's overall favorable tolerability and acceptable safety profile.   Our second in-licensed patented program is being advanced from our platform of small-molecule inhibitors of FABPs, notably FABP5.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ENVB | Enveric Biosciences, Inc. | USD 1.39 | ▼ 3.47% |
| ITRMF | Iterum Therapeutics plc | USD 0 | ▲ 0% |
| DCOY | Decoy Therapeutics Inc. | USD 2.69 | ▼ 9.73% |
| RKTO | Rocket One Inc. | USD 0.69 | ▲ 0.48% |
| ADTX | Aditxt, Inc. | USD 0.01 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:24 UTC. This page is informational and not investment advice.